Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of CYT-0851

2021-06-04T13:19:59-04:00

Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of CYT-0851 Phase 1 interim analysis data presented at oral session at the annual meeting of the American Society of Clinical Oncology (ASCO) Treatment-related adverse events occurred infrequently and were low-grade and manageable Responses during dose-escalation have been observed in patients with DLBCL, follicular lymphoma [...]